ArticleJournal of gastrointestinal oncology2025
Predictive factors for successful conversion therapy in gastric cancer with peritoneal metastasis: a case-control study.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) patients with peritoneal metastasis (PM) have a poor prognosis. Little is known about factors for successful conversion therapy in GC with PM. This study aimed to identify early predictive factors associated with R0 resection in GC patients with PM undergoing conversion therapy. Methods: We retrospectively analyzed 108 patients diagnosed with PM via laparoscopic exploration and treated systemically at The First Affiliated Hospital of Xi'an Jiaotong University (2019-2023). Prognostic outcomes were evaluated using Kaplan-Meier analysis, and logistic regression was employed to identify factors influencing conversion therapy success. Results: In total, 108 patients with PM were included in the study, 21 of whom underwent R0 resection after conversion therapy (R0 resection rate, 19.4%). Patients in the conversion surgery (CS) group had a significantly longer median overall survival than those in the non-CS group (P<0.001). Multivariate analysis revealed that elevated carbohydrate antigen 125 (CA125) levels [odds ratio (OR): 5.449, 95% confidence interval (CI): 1.425-20.830; P=0.01] were a risk factor for the failure of conversion therapy in GC patients with PM. Treatment with a programmed death 1 (PD-1) inhibitor (OR: 0.285, 95% CI: 0.099-0.820, P=0.02) was a protective factor against the failure of conversion therapy in GC patients with PM. Conclusions: Achieving R0 resection through conversion therapy can significantly improve the prognosis of GC patients with PM. For patients with no significant elevation of CA125, it is advisable to consider implementing an aggressive first-line regimen in conjunction with a PD-1 inhibitor for the purpose of conversion therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.